KODIAK SCIENCES INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.03 USD | -1.30% |
|
-6.23% | -0.99% |
Financials (USD)
| Sales 2024 * | - | Sales 2025 * | - | Capitalization | 161M |
|---|---|---|---|---|---|
| Net income 2024 * | -184M | Net income 2025 * | -262M | EV / Sales 2024 * | - |
| Net cash position 2024 * | 98.72M | Net Debt 2025 * | 8.24M | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-0.85
x | P/E ratio 2025 * |
-0.74
x | Employees | 107 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 94.34% |
More Fundamentals
* Assessed data
More news
Latest transcript on Kodiak Sciences Inc.
More recommendations
More press releases
| 1 day | -1.29% | ||
| 1 week | -5.83% | ||
| Current month | -4.36% | ||
| 1 month | -6.40% | ||
| 3 months | -50.00% | ||
| 6 months | +20.87% | ||
| Current year | +0.99% |
1 week
3.04
3.38
1 month
3.044.08
Current year
2.877.77
1 year
1.379.80
3 years
1.37131.97
5 years
1.37171.21
10 years
1.37171.21
| Managers | Title | Age | Since |
|---|---|---|---|
Victor Perlroth
CEO | Chief Executive Officer | 51 | 08-12-31 |
John Borgeson
DFI | Director of Finance/CFO | 62 | 15-12-31 |
| Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Felix Baker
BRD | Director/Board Member | 55 | 15-08-31 |
Tai Yin Yang
BRD | Director/Board Member | 70 | 19-12-16 |
Richard Levy
BRD | Director/Board Member | 66 | 18-07-17 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.04% | 0 M€ | 0.00% | - | |
| 0.03% | 0 M€ | 0.00% | - | |
| 0.00% | 9 M€ | +10.11% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-28 | 3.03 | -1.30% | 598 741 |
| 24-05-24 | 3.07 | -1.29% | 128,295 |
| 24-05-23 | 3.11 | -4.60% | 656,895 |
| 24-05-22 | 3.26 | +1.56% | 570,747 |
| 24-05-21 | 3.21 | -1.53% | 252,217 |
Delayed Quote Nasdaq, May 24, 2024 at 04:00 pm EDT
More quotes
Kodiak Sciences Inc. is a biopharmaceutical company. The Company has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) Platform, for retinal medicines. Its ABC Platform uses molecular engineering to merge the fields of protein-based and chemistry-based therapies. Its lead investigational medicine, tarcocimab, is a novel anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer conjugate under development for the treatment of high prevalence retinal vascular diseases, including diabetic retinopathy, the cause of blindness in working-age patients in the developed world, and wet age-related macular degeneration, the cause of blindness in elderly patients. Its second investigational medicine, KSI-501, is a bispecific antibody biopolymer conjugate targeting the pro-inflammatory cytokine interleukin-6 (IL-6) and VEGF. It is also developing a third investigational medicine, KSI-101, an unconjugated bispecific protein targeting IL-6 and VEGF.
Calendar
2024-06-04
- Annual General Meeting
Related indices
Sell
Buy
Mean consensus
HOLD
Number of Analysts
7
Last Close Price
3.07
USD
Average target price
4.25
USD
Spread / Average Target
+38.44%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +0.99% | 161M | |
| +12.30% | 118B | |
| +12.15% | 106B | |
| -8.14% | 23.4B | |
| -0.29% | 22.1B | |
| -9.28% | 18.34B | |
| -41.70% | 16.59B | |
| -15.33% | 15.97B | |
| +5.80% | 14.03B | |
| +28.03% | 11.67B |
- Stock Market
- Equities
- KOD Stock
